VE-5773

VE-5773 is a study identifier (GS-US-540-5773) for a Phase 3 clinical trial conducted by Gilead Sciences, investigating the antiviral drug remdesivir (brand name VEKLURY) for the treatment of severe COVID-19. Remdesivir is a nucleotide analog that acts by inhibiting viral RNA-dependent RNA polymerase, an enzyme essential for the replication of RNA viruses like SARS-CoV-2. This inhibition disrupts the viral replication process, thereby reducing the viral load and potentially improving clinical outcomes in infected patients. The study aimed to evaluate the efficacy and safety of remdesivir administered intravenously for 5 or 10 days in hospitalized adult patients with confirmed SARS-CoV-2 infection.

Brand names

VEKLURY

Other names

remdesivir